Insider trade

Officer received an award of 3,940 JNJ derivative securities

Traded Feb 15, 2026 · Filed Feb 19, 2026

Johnson & JohnsonJNJ

3,940
Derivative units

Why it stands out

Compensation award — excluded from discretionary-purchase analysis.

Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell

View the official recordSEC Form 4 — Statement of Changes in Beneficial Ownership

All the details

Dates, kept separate

Transaction date: Feb 15, 2026
Reporting period: Not applicable
Filed with the SEC: Feb 19, 2026

OfficerGrant / award

Context

Classification

grant award

Code A — grant or award

Planned / mechanical clue

Footnote references vesting of compensation awards

Only flagged when a footnote says so; never inferred

Source receipt

Record ID: 0000200406-26-000037
Filed / recorded

Feb 19, 2026, 2:11 AM UTC

Added to OQRO

Oct 2, 2026, 3:52 AM UTC

Parser

form4-xml-v1

Data quality

Verified: identifiers matched exactly

Issuer

JOHNSON & JOHNSON

Issuer CIK

200406

Ticker

JNJ

Reporting person

Jennifer L Taubert

Relationship

Officer

Officer title

EVP, WWC. Innovative Medicine

Security

Restricted Share Units

Table

Derivative (Table II)

Transaction date

Feb 15, 2026

Transaction code

A

Shares / units

3,940

Price per share

$0.00

Acquired / disposed

Acquired (A)

Shares owned after

3,940

Ownership form

Direct

Amendment

No

Footnotes from the filing

Awarded under Issuer's Long-Term Incentive Plan. The Restricted Share Units (RSUs) awarded on February 15, 2026 vest in three annual equal installments beginning on the first anniversary of the grant date. The RSUs convert into shares of Common Stock upon vesting on a one for one basis.
Each RSU represents a contingent right to receive one share of Company Common Stock.